Jubilant Ingrevia Ltd
Jubilant Ingrevia Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Specialty Chemicals volume growth has been double-digit over the past years, expected to continue. Specialty Chemicals segment aims for at least 20% CAGR EBITDA growth over a multi-year horizon, maintaining stable EBITDA margins around 25-26%.
From Jubilant Ingrevia Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Specialty Chemicals volume growth has been double-digit over the past years, expected to continue.
- Pricing has bottomed out recently, with signs of marginal price increases in some segments.
- FY '27 is considered a pivotal year to fill new capacity, including the new CDMO agro plant, with significant volume growth expected.
- 16 molecules confirmed with peak potential of INR1,400 crore; 80+ molecules in pipeline, implying future revenue growth over 3-4 years.
- Nutritional & Health Solutions showed volume growth; cosmetic grade and food grade products maintain steady growth.
- CDMO agro project shipment to start March 2026, with scaling expected in FY '27 and beyond.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Jubilant Ingrevia Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Year-to-date capex of INR366 crore primarily spent on the upcoming CDMO agro plant at Bharuch and new multipurpose facility at Gajraula.
- Planned capex of approximately INR500 crore in FY 2027, funded mainly through internal accruals.
- Commissioned a new boiler at Bharuch site in Q3 FY '26 to enhance operational efficiency.
- Agro innovator project commissioning on track, expected to start dispatching volumes from March 2026.
- Construction commenced on a new multipurpose plant at Gajraula to add flexibility and capacity to CDMO and fine chemicals portfolio.
2 more points management made on capital expenditure plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jubilant Ingrevia Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Jubilant Ingrevia has an expanded opportunity funnel of over 100 active CDMO opportunities with a peak annual revenue potential of approximately INR 3,500 crore.
- In the past year, more than 16 molecules have been confirmed with an estimated peak potential of INR 1,400 crore.
- Advanced discussions are ongoing for over 7 additional opportunities valued at around INR 900 crore.
- The CDMO contracts have visibility for the first few months and shipments for a large agrochemical order are expected to start by mid-March FY '26.
2 more points management made on order book & pipeline
Jubilant Ingrevia Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.2K Cr, net profit ₹86 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jubilant Ingrevia Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q4 FY25 earnings call →
- Q3 FY25 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
Others in Chemicals & Petrochemicals this season
- Balaji Amines Ltd (Q3 FY26)
Revenue from Operations for Q3FY26: ₹331.30 crore, compared to ₹320.59 crore in Q3FY25 (consolidated) and ₹304.68 crore in Q3FY25 (standalone). Key concall…
- Vidhi Specialty Food Ingredients Ltd (Q3 FY26)
94.5 Cr, down 4.1% YoY from Rs. Key concall takeaways from Vidhi Specialty Food Ingredients Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- Bodal Chemicals Ltd (Q3 FY26)
5,046.6 Mn, up 13.3% YoY (Q3 FY25: Rs. Key concall takeaways from Bodal Chemicals Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- Chemcon Speciality Chemicals Ltd (Q3 FY26)
Q3 FY26 Revenue from Operations:** ₹57.3 Cr (vs ₹54.4 Cr in Q3 FY25) — approx. Key concall takeaways from Chemcon Speciality Chemicals Ltd's Q3 FY26 earnings…
Frequently Asked Questions
What were Jubilant Ingrevia Ltd Q3 FY26 results?
Specialty Chemicals volume growth has been double-digit over the past years, expected to continue. Specialty Chemicals segment aims for at least 20% CAGR EBITDA growth over a multi-year horizon, maintaining stable EBITDA margins around 25-26%.
What is Jubilant Ingrevia Ltd share price analysis?
Jubilant Ingrevia Ltd currently shows a neutral. The stock trades at a P/E of 36.9 with a market cap of ₹11,738 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jubilant Ingrevia Ltd planning capital expenditure?
Year-to-date capex of INR366 crore primarily spent on the upcoming CDMO agro plant at Bharuch and new multipurpose facility at Gajraula.
Keep Jubilant Ingrevia Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.